Zobrazeno 1 - 10
of 100
pro vyhledávání: '"Michael A. Nauck"'
Publikováno v:
Diabetologie und Stoffwechsel. 16:225-231
ZusammenfassungEine Patientin wurde aufgrund rezidivierender postprandialer Hypoglykämien nach Roux-en-Y-Magenbypass mit Diazoxid behandelt, nachdem eine Ernährungsumstellung keine Symptomlinderung erzielt hatte. Nach Eindosierung von Diazoxid mit
Autor:
Juris J. Meier, Michael A. Nauck, Waldemar Uhl, Thomas G. K. Breuer, Daniel R. Quast, Monika Janot-Matuschek
Publikováno v:
Diabetologie und Stoffwechsel. 16:130-140
Zusammenfassung Einleitung Pankreasresektionen werden bei schwerwiegenden Pankreaserkrankungen durchgeführt. Bei Komplikationen einer chronischen Pankreatitis, teilweise jedoch auch bei Raumforderungen, kann eine Pankreasteilresektion sinnvoll sein.
Publikováno v:
Diabetes Care. 44:479-488
OBJECTIVE Acute experimental variations in glycemia decelerate (hyperglycemia) or accelerate (hypoglycemia) gastric emptying. Whether spontaneous variations in fasting plasma glucose (FPG) have a similar influence on gastric emptying is yet unclear.
Autor:
Julie Broe Honore, Johannes F.E. Mann, Richard E. Pratley, Bernard Zinman, Subodh Verma, Michael A. Nauck, John B. Buse, Søren Rasmussen, Stephen C. Bain, Maria Sejersten Ripa
Publikováno v:
Diabetes, Obesity & Metabolism
The randomized, double‐blind, cardiovascular outcomes trials LEADER (NCT01179048) and SUSTAIN 6 (NCT01720446) showed cardiovascular risk reduction in patients with type 2 diabetes treated with liraglutide and semaglutide, respectively, compared wit
Autor:
Shweta Urva, Emily C Beebe, Michael A. Nauck, Charles Benson, Xuewei Cui, Tamer Coskun, Corina Loghin, Libbey S. O’Farrell, Daniel A. Briere, Axel Haupt
Publikováno v:
Diabetes, Obesity and Metabolism. 22:1886-1891
The effect of dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist (RA) tirzepatide on gastric emptying (GE) was compared to that of GLP-1RAs in non-clinical and clinical studies. GE was assesse
Autor:
Klara R. Klein, John B. Buse, Frederik Flindt Kreiner, Michael A. Nauck, Anna R. Kahkoska, Nikolaus Marx, Benjamin Wolthers, Richard E. Pratley, Milan S. Geybels
Publikováno v:
Diabetes, Obesity and Metabolism. 22:1537-1547
AIMS To validate the clusters of Swedish individuals with recent-onset diabetes at differential risk of complications, which were identified in a previous study, in three global populations with long-standing type 2 diabetes (T2D) who were at high ca
Autor:
Stephen C. Bain, Richard E. Pratley, Steven E. Nissen, Tea Monk Fries, Michael A. Nauck, Martin Linder, Bernard Zinman, Neil R Poulter, David D. Ørsted, Johannes F.E. Mann, John B. Buse, Stuart J. Pocock
Publikováno v:
Diabetes Care
OBJECTIVE The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial (ClinicalTrials.gov reg. no. NCT01179048) demonstrated a reduced risk of cardiovascular (CV) events for patients with type 2 diabetes
Autor:
Axel Haupt, Xuewei Cui, Michael A. Nauck, Shweta Urva, Joanna Van, Zvonko Milicevic, Deborah A. Robins, Ross Bray, Juan P. Frias, Charles Benson
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To assess the efficacy and tolerability of tirzepatide treatment using three different dose‐escalation regimens in patients with type 2 diabetes. Materials and Methods In this double‐blind, placebo‐controlled study, patients were randomized
Publikováno v:
Diabetes, Obesity and Metabolism. 22:699-704
Some epidemiological data have suggested an elevated risk of acute pancreatitis and pancreatic cancer after exposure to glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase (DPP)-4 inhibitors. Recently, such outcomes have been ass
Autor:
Kerstin Stemmer, Stephen C. Woods, Harvey J. Grill, Jens J. Holst, Alessandro Pocai, Michael A. Nauck, Andreas Fritsche, Richard D. DiMarchi, David A. D'Alessio, Mads Tang-Christensen, Diego Perez-Tilve, Darleen A. Sandoval, Randy J. Seeley, Wolfgang Langhans, Daniel J. Drucker, Stephen R. Bloom, M.H. Tschöp, Brian Finan, Fiona M. Gribble, Timo D. Müller, Peter R. Flatt, Joel F. Habener, Juris J. Meier, Thue W. Schwartz, Frank Reimann
Publikováno v:
Molecular Metabolism, Vol 30, Iss, Pp 72-130 (2019)
Molecular Metabolism
Molecular Metabolism, 30
Mueller, T D, Finan, B, Bloom, S R, D'Alessio, D, Drucker, D J, Flatt, P R, Fritsche, A, Gribble, F, Grill, H J, Habener, J F, Holst, J J, Langhans, W, Meier, J J, Nauck, M A, Perez-Tilve, D, Pocai, A, Reimann, F, Sandoval, D A, Schwartz, T W, Seeley, R J, Stemmer, K, Tang-Christensen, M, Woods, S C, DiMarchi, R D & Tschoep, M H 2019, ' Glucagon-like peptide 1 (GLP-1) ', Molecular Metabolism, vol. 30, pp. 72-130 . https://doi.org/10.1016/j.molmet.2019.09.010
Molecular Metabolism
Molecular Metabolism, 30
Mueller, T D, Finan, B, Bloom, S R, D'Alessio, D, Drucker, D J, Flatt, P R, Fritsche, A, Gribble, F, Grill, H J, Habener, J F, Holst, J J, Langhans, W, Meier, J J, Nauck, M A, Perez-Tilve, D, Pocai, A, Reimann, F, Sandoval, D A, Schwartz, T W, Seeley, R J, Stemmer, K, Tang-Christensen, M, Woods, S C, DiMarchi, R D & Tschoep, M H 2019, ' Glucagon-like peptide 1 (GLP-1) ', Molecular Metabolism, vol. 30, pp. 72-130 . https://doi.org/10.1016/j.molmet.2019.09.010
Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying, in